Deana Mohr

Multisystem Cell Therapy for Improvement of Urinary Continence (MUS.I.C) REACHING THE PEOPLE

Stress Urinary Incontinence (SUI), defined as the unintentional loss of urine, affects over 200 million people worldwide, with a prevalence of 20-50% in women. The currently available treatment options entail various complications. In the lab of Prof. Daniel Eberli, Deana Mohr finalized the development of a technology in tissue engineering using autologous muscle cells. This technology offers functional restoration of the damaged urinary sphincter muscle, thereby, representing an ideal treatment option that could reverse the underlying pathologic condition. During the Fellowship, Deana Mohr and her team plan to perform the necessary steps to bring this therapy to the people in need. This includes demonstrating the commercial potential of the approach, protecting the innovations, perform market research and setup an investment schema for the near and far future.

Affiliation: Prof. Daniel Eberli

Start date: 07/2019

Milestones

Deana Mohr co-founded the UZH Spin-off MUVON Therapeutics AG in 2019
MUVON is being accelerated by Wyss Zurich in 2021
MUVON Therapeutics selected as finalist for the 2021 >>venture>> Startup Competition
MUVON wins second place at IFAS Innovation Challenge 2021
MUVON finishes as Top 3 finalist for the ZKB Pionierpreis 2023